AstraZeneca Appoints Joris Silon As Head Of Investor Relations Effective March 2026

AstraZeneca has announced the appointment of Joris Silon as its new Head of Investor Relations, effective 1 March 2026. He will succeed Andy Barnett in the role and will be based in Cambridge, UK, supporting the company’s global investor engagement and communications strategy.

Silon transitions into the position from his role as AstraZeneca’s U.S. country president, where he led the company’s largest market and delivered strong growth performance. His leadership in the U.S. has been marked by commercial execution and strategic expansion across key therapeutic areas.

Aradhana Sarin, Chief Financial Officer, said “I am delighted that such a highly experienced and talented leader as Joris will lead our Investor Relations team through our next wave of growth. I would also like to thank Andy Barnett for his remarkable leadership of our Investor Relations team over the past 4 years and wish him the best of luck as he transitions to an important new role within the Company.”

Having joined AstraZeneca in 2000, Silon brings more than two decades of experience within the company. He has held a range of senior leadership roles across Asia, Europe, and the United States, which has provided him with a broad global perspective on the pharmaceutical industry and AstraZeneca’s operations.

AstraZeneca is a global, science-driven biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across oncology, rare diseases, and biopharmaceuticals. Headquartered in Cambridge, UK, the company’s medicines are available to patients in more than 125 countries worldwide.